

Supplementary Material

Supplementary Table 1. Cannabis strains available in Germany in 2020 at the time of study conduction included in the survey in alphabetical order (N=43). Characteristics of strains are described according to [24], [25].

Strain	THC %	CBD %	Type of strain	Cultivar
Argyle	5.4	7	Indica	
Aurora 1/12	0.5	12.5	Hybrid	Cannatonic
Aurora 1/15	1	15	Hybrid	
Bakerstreet	18.9	0.5	Indica	Hindu Kush, Herijuana & Afghanic
Bedica	15.8	0.1	Indica	
Bediol	6.3	8.3	Sativa	Elida, Jack Herres & Afganic
Bedrobinol	13.1	0.1	Hybrid	
Bedrocan	21.7	0.1	Hybrid	Jack Herres
Bedrolite	1	9	Sativa	
Cannamedical Hybrid Forte Headband	24	1	Hybrid	Headband
Cannamedical Hybrid Jean Guy	20	1	Hybrid	Jean Guy
Cannamedical Hybrid Light Jean Guy	16	1	Hybrid	Light Jean Guy
Cannamedical Hybrid Vita	13.5	1	Hybrid	
Cannamedical Indica Forte	24	1	Indica	
Cannamedical Indica Light Mango	16	1	Indica	Mango
Cannamedical Indica Sirius	20	1	Indica	Sirius

Cannamedical Indica Vita	13.5	1	Indica	
Cannamedical Sativa	20	1	Sativa	
Cannamedical Sativa Forte	24	1	Sativa	
Cannamedical Sativa Light	16	1	Sativa	Amnesia Haze
Cannamedical Sativa Vita	13.5	1	Sativa	Amnesia Haze
Green no. 3	8.1	11.1	Hybrid	
Klenk 18/1	19.6	0.1	Hybrid	
Natural 18/1 CA Indica	18	1	Indica	
Natural 25/1 CA Hybrid	25	1	Hybrid	
Orange no. 1	11.56	0.5	Indica	
Peace Naturals 14/1	14.3	0.3	UN	
Peace Naturals 16/1	15.7	0.3	Hybrid	
Peace Naturals 18/1	16.6	0.3	Indica	
Peace Naturals 20/1	20.4	1	Indica	
Pedarios 14/1	14.3	0.3	Sativa	Banana Split
Pedarios 16/1	16	1	UN	
Pedarios 18/1	18	1	Indica	Sour Tangie
Pedarios 20/1	19.3	0.1	Indica	L.A. Confidential
Pedarios 22/1	21.4	1	Sativa	Ghost Train Haze
Pedarios 8/8	7.6	8	Hybrid	
Penelope	8.6	6.9	Hybrid	CBD Skunk Haze
Red no. 2	16.1	0.5	Sativa	Lemon Skunk

Red no. 4	19.5	0.5	Indica	Crimea Blueberry
Tilray THC 10/CBD 10	10	10	Hybrid	Warlock CBD
Tilray THC 25 (Headband)	23.3	1	Sativa	Headband
Tilray THC 25 (Rockstar)	24.5	1	Indica	Rockstar
Tilray THC25 Hybrid (Purps)	25.4	1	Hybrid	Purps

THC – tetrahydrocannabinol, CBD – cannabidiol, UN – unknown

Supplementary Table 2. Indications for medicinal cannabis (MC) specified by diseases and diagnostic categories, as well as treatment time (ever versus currently) in 1,028 patients. The table shows the number of patients who selected a particular disease as an indication for MC use, and the number of indications in the selected disease category. For example, 659 participants selected the category of pain syndromes in the category “ever treated.” Since multiple selections in this category were possible, altogether 1,277 pain syndromes were selected, which constituted 34.3% of all listed disorders. In contrast, in the category of the current indication (“currently treated”), each participant could only select one disease; therefore, the number of participants in each group and the number of selections are identical. The indications selected >100 times for “ever treated” are listed in italics.

Disease belonging to the particular category	Ever treated		Currently treated	
	N (%)	Sum (N, %)	N (%)	Sum (N, %)
Pain syndromes	659	1277 (34.3%)	441	441 (42.9%)
Chronic pain	273 (7.3%)		120 (11.7%)	
<i>Musculoskeletal pain</i>	377 (10.1%)		123 (12.0%)	
<i>Neuropathic pain</i>	224 (6.0%)		60 (5.8%)	
Pain in MS	28 (0.8%)		11 (1.1%)	
Pain provoked by paresis	25 (0.7%)		9 (0.9%)	
Fibromyalgia	82 (2.2%)		31 (3.0%)	


<i>Migraine and other headaches</i>	182 (4.9%)		64 (6.2%)	
Endometriosis	9 (0.2%)		2 (0.2%)	
Other pain syndromes	77 (2.1%)		21 (2.0%)	
Neurological disorders	239		125	
Spasticity in MS	44 (1.2%)		25 (2.4%)	
Other symptoms in MS	42 (1.1%)		14 (1.4%)	
Spasticity in ALS	1 (0.0%)		0 (0%)	
Spasticity related to paresis	7 (0.2%)		1 (0.1%)	
Spasticity related to other disorders	27 (0.7%)		5 (0.5%)	
Parkinson's disease	3 (0.1%)		1 (0.1%)	
Dystonia	6 (0.2%)	339 (9.1%)	0 (0.0%)	125 (12.2%)
Tourette syndrome	27 (0.7%)		24 (2.3%)	
RLS	93 (2.5%)		31 (3.0%)	
Essential tremor	6 (0.2%)		0 (0%)	
Epilepsy	22 (0.6%)		10 (1%)	
TBI/Stroke	16 (0.4%)		2 (0.2%)	
Other neurological disorders	45 (1.2%)		12 (1.2%)	
Psychiatric disorders	517		303	
<i>ADHD</i>	213 (5.7%)		133 (12.9%)	
<i>PTSD</i>	143 (3.8%)	1295 (34.7%)	56 (5.4%)	303 (29.5%)
<i>Sleeping problems</i>	297 (8.0%)		32 (3.1%)	
OCD	31 (0.8%)		1 (0.1%)	

Autism	21 (0.6%)		9 (0.9%)	
<i>Depression</i>	302 (8.1%)		43 (4.2%)	
<i>Anxiety</i>	200 (5.4%)		21 (2.0%)	
Substance abuse disorder	57 (1.5%)		2 (0.2%)	
Other psychiatric disorders	28 (0.8%)		6 (0.6%)	
Gastrointestinal diseases	212		51	
<i>IBD</i>	61 (1.6%)		31 (3.0%)	
Nausea related to chemotherapy	4 (0.1%)	262 (7.0%)	1 (0.1%)	51 (5.0%)
Nausea related to IBS	55 (1.5%)		3 (0.3%)	
Other GI disorders	41 (1.1%)		4 (0.4%)	
Pulmonary disorders	96		13	
Asthma	71 (1.9%)	107 (2.9%)	9 (0.9%)	13 (1.3%)
COPD	17 (0.5%)		2 (0.2%)	
Other pulmonary disorders	19 (0.5%)		2 (0.2%)	
Skin conditions	103		24	
Pruritus	33 (0.9%)		4 (0.4%)	
Sweating	18 (0.5%)	139 (3.7%)	3 (0.3%)	24 (2.3%)
Acne inversa	20 (0.5%)		11 (1.1%)	
Psoriasis	29 (0.8%)		3 (0.3%)	
Other skin conditions	39 (1.0%)		3 (0.3%)	
Otolaryngological conditions	65		11	
Tinnitus	56 (1.5%)	72 (1.9%)	8 (0.8%)	11 (1.1%)

Other otolaryngological conditions	16 (0.4%)		3 (0.3%)	
Ophthalmological conditions	18		2	
Glaucoma	8 (0.2%)	19 (0.5%)	1 (0.1%)	2 (0.2%)
Other ophthalmological conditions	11 (0.3%)		1 (0.1%)	
Other diseases belonging to internal medicine	101		23	
Loss of appetite in AIDS	4 (0.1%)		1 (0.1%)	
Loss of appetite in cancer	14 (0.4%)		2 (0.2%)	
Loss of appetite related to aging	7 (0.2%)	114 (3.1%)	0 (0%)	23 (2.2%)
Diabetes	17 (0.5%)		0 (0%)	
Rheumatologic arthritis	46 (1.2%)		16 (1.6%)	
Other diseases in this category	26 (0.7%)		4 (0.4%)	
Other diseases	104 (2.8%)	104 (2.8%)	35 (3.4%)	35 (3.4%)

MS – multiple sclerosis, ALS – amyotrophic lateral sclerosis, RLS – restless legs syndrome, TBI – traumatic brain injury, ADHD – attention-deficit/hyperactivity disorder, PTSD – post-traumatic stress disorder, OCD – obsessive-compulsive disorder, IBD – inflammatory bowel disease, IBS – irritable bowel syndrome, GI – gastrointestinal, COPD – chronic obstructive pulmonary disease, AIDS – acquired immunodeficiency syndrome

Supplementary Figure 1. Concentrations of tetrahydrocannabinol to cannabidiol (THC:CBD) in medical cannabis strains “frequently” prescribed (defined as > 30 times, N=1,028 patients).



Supplementary Figure 2. Patient-reported effectiveness of different medical cannabis (MC) strains used as first choice (mean efficacy = 80.1%, range, 6-100%) rated on a scale ranging from 0% (=no effect) to 100% (=optimal effect/symptom free).

